Study register · detailKohortenstudie · Psychosis · 2016
Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit et al.·The Journal of clinical psychiatryImpact 2.2
UnclearGRADELow29 citations
Samplen = 223 Pat.
DurationOctober 2007 to May 2014
ControlCannabis users
EndpointPANSS
Blindingn.a.
DesignKohortenstudie
”Key finding
Synthetic cannabinoid users showed more severe psychotic symptoms, longer hospitalisation duration and more previous hospitalisations than cannabis users, but this is a comparative observational study without an intervention effect.
Summary
n=223 psychiatrically hospitalised patients (synthetic cannabinoids n=60 vs. cannabis n=163); SC users younger (30,5±7,8 vs. 34,7±10,1 years, p=0.009), longer hospitalisation (43,5±54,0 vs. 22,9±31,4 days, p=0.005), more previous hospitalisations (3,7±5,1 vs. 2,0±5,1, p<0.001), higher PANSS scores (82,5±23,1 vs. 70,0±19,9, p=0.008), more frequently court-ordered admissions (36,7% vs. 19,9%, p=0.028).
P
PopulationPsychiatric inpatients with synthetic cannabinoid (SC) use (n=60) vs. cannabis users (n=163), retrospective
ControlCannabis users (THC-positive urine test without SC history)
O
OutcomeSC users younger (30,5 vs. 34,7 years, p=0,009), longer hospitalisation (43,5 vs. 22,9 days, p=0,005), more previous admissions (3,73 vs. 1,98, p<0,001), higher PANSS total score (82,5 vs. 70,0, p=0,008); more frequently court-ordered admission (36,7% vs. 19,9%, p=0,028)
Confidence in the evidence
Very lowLowModerateHigh
Low
The second of four GRADE levels, the effect estimate is of limited reliability.
Quality profile
Sample size★★★★★
Blinding—
Effect size—
Citations / year★★★★★
Authors
Shalit N, Barzilay R, Shoval G, Shlosberg D, Mor N, Zweigenhaft N, Weizman A, Krivoy A
Background: Psychotic and affective exacerbations associated with synthetic cannabinoid (SC) use are becoming an emerging concern in psychiatric hospitals. However, data are lacking regarding whether clinical manifestations of SC use differ from those associated with cannabis use.
Objective: Our aim was to explore the unique profile of SC users admitted to a mental health center in terms of demographic, clinical, and physiologic variables in comparison to cannabis users.
Methods: We retrieved retrospective data of patients admitted to a mental health center between October 2007 and May 2014 who self-reported recent use of SC (n = 60) and patients who were cannabis users (positive carboxy-tetrahydrocannabinol urine test at admission) without a history of SC use (n = 163). Clinical measures included hospitalization length, number of previous hospitalizations, Positive and Negative Syndrome Scale (PANSS) scores, psychiatric status at admission, and relevant physiologic and laboratory parameters.
Results: Hospitalized SC users were younger than hospitalized cannabis users (n = 163) (30.46 +/- 7.83 years versus 34.67 +/- 10.07 years, U(2)(2)(3) = 3,781.5, P = .009, respectively). SC patients had longer hospitalizations compared to cannabis users (43.45 +/- 54.02 days versus 22.91 +/- 31.36 days, U(2)(1)(9) = 5,701.5, P = .005, respectively), had more previous hospitalizations (3.73 +/- 5.05 versus 1.98 +/- 5.12, U(2)(2)(3) = 6,284, P < .001, respectively), and were more likely to be hospitalized by criminal court order (36.7% [n = 22] versus 19.9% [n = 32], chi(2)(2) = 7.136, P = .028, respectively). SC patients presented with a more severe clinical picture manifested by higher total PANSS scores (82.53 +/- 23.05 versus 69.98 +/- 19.94, t(9)(1) = -2.696, P = .008) in a subset of patients with PANSS scores assessed within a week from admission (n = 30 in the SC group and n = 63 in the cannabis group). No differences were found in physiologic or laboratory measures on admission between the SC and cannabis groups.
Conclusions: Patients admitted following use of SC are generally younger males who have higher severity of psychotic symptoms at admission, are more likely to be admitted by criminal court order, and require longer hospitalization periods in comparison to cannabis users.